Antifungal agents Flashcards
Risk factors of fungal infections
neutropenia, corticosteroids, TPN, plonged or excessive use, CVLs, mechanical ventilation, CRRT, immunosuppressants
Most commonly encountered fungi
candida species: c. albicans, c. glabrata, c. parapsilosis, C. krusei, asperigllus, histoplasmosis (midwest)
Azoles options
fluconazole (diflucan), itraconazole (Sporanox), voriconazole (Vfend), posaconazole (noxafil)
Echinocandins options
anidulafungin (Eraxis), caspofungin (Cancidas), micafungin (Mycamine)
Imidazole options
ketoconazole (Nizoral), clotrimazole, miconazole
Micallaneous options
amphotericin B (Fungizone), liposomal amphotericin B, flucytosine (Ancobon), nystatin, terbinafine (Lamisil)
Azole MOA
Inhibits synthesis of ergosterol by inhibiting fungal CY450 enzymes, blocked formation of the critical ergosterol component results in a damaged fungal cell membrane and leakage of cytoplasm to inhibit cell growth, fungistatic
difulcan spectrum of activity
candida, less against C. glabrata, histoplasma capsulatum, blastomyces dermatitides, coccidioides immitis
what are difulcan not affected against?
C. Krusei, aspergillus
PK of difulcan
great absorption orally regardless of gastric pH which is unique to this drug, IV/PO, great system wide penetration, excreted unchanged in urine, renal adjustment
Clinical use of difulcan
most commonly used antifungal, Candidiasis DOC, oropharyngeal, esophageal, systemic, UTI, fungemia, cryptococcal meningitis
ADR of Difulcan
very well tolerated, elevation of LFT, N/V
DI of difulcan
worry more about these, HCTZ, warfarin, phenytoin
Dosing of difulcan
topical candidiasis- 100-200 mg PO QD, non-invasive candidiasis- 200-400 mg/d, invasic=ve- push the dose- 400-800 mg/d
itraconazole MOA
inhibits ergosterol synthesis, fungistatic
Spectrum of activity of itraconazole
asperigillus, candida, cryptococcus neoformans, histoplasma capsulatum, blastomyces dermatitidis
clinical use of itraconazole
reserved for more rare fungal infections, blastomycosis, histoplasmosis, life-threatening infxn, aspergillosis, onchomycosis of finger and toes, esophageal/oropharyngeal
Voriconazole MOA
inhibits ergosterol synthesis, fungistatic
Voriconazole spectrum
aspergillus, including amphotericin resistant, all candida, cryptococcus neoformans
Voriconazole kinetics
IV/PO, great Vd, not nephrotoxic but vehicle it is compounded to is, IV contraindicated in
DI of voriconazole
lots, has activity of most cyp 450 enzymes, major limitation but still used when needed
Voriconazole clinical uses
invasive aspergillosis, pt usually get dual therapy and voriconazole, other serious fungal infxns, drug resistant candidiasis
Posaconazole (noxafil) MOA
inhibits ergosterol synthesis, fungistatic, similar to itraconazole, only available as a liquid
Spectrum of activity of posaconazole
aspergillus, candida, cryptococcus neoformans, very broad
posaconazole clinical use
long term as prophylaxis for aspergillosis in immunocompromised, must take with food
Ketoconazole moa
inhibits synthesis ergosterol, blocks formation of ergosterol damages fungal cell membrane and destroys structural integrity, fungistatic